News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$LUDG Connection to Nike! This is crazy.
So the Director of Data Science at Nike’s Consumer Data Science division now worked for $LUDG on a big project.
Dr. Ambert is currently the Director of Data Science at Nike’s Consumer Data Science division after holding several positions as a data and artificial intelligence scientist. Before Nike Dr. Ambert was the Senior Deep Learning Data Scientist at Intel. His responsibilities at Intel included Data Scientist roles in Artificial Intelligence & Applied Analytics Group, Health & Life Sciences: Big Data Solutions Group and Biomedical & Big Data Research
BOOOOOOOM $LUDG
More LUDG. The DD is intense.
UPlisting already in progress now as well.
Now, look at how much insides NOW own.
Can't believe more people are not talking about this. $LUDG
SPARKS, Nev., March 06, 2024 (GLOBE NEWSWIRE) -- Ludwig Enterprises, Inc. (OTC: LUDG): A US-based biotechnology company is pleased to announce the successful filing of its provisional patent, title “mRNAs differentially expressed in colorectal cancer, breast cancer, and bladder cancer.” By utilizing machine learning artificial intelligence (AI), this breakthrough is able identify specific mRNA genes associated with breast, colorectal, and bladder cancer.
These genetic findings marks a significant milestone for the company, and positions it to enter, this year, into the billion dollar diagnostic cancer screening market. The Company’s mRNA for Life™ is a one-of-the-kind noninvasive at-home sceening test for genes that could be associated with cancer. This test allows a person to make themselves a priority and could be a signal to seek a medical examination.
Ludwig, over the past 3 years, has received over 2,500 nonivasive cheek cell samples from numerous clinics in the United States as part of an IRB approved clinical study of patients with various diseases. The Company selected for measurement 48 distinct mRNA genes in stored specimens from patients afflicted with breast, bladder or colorectal cancer. mRNA levels were analyzed using machine learning artificial intelligence (AI) to identify markers of genetic expression involved in separate cancers. The filed patent application describes a method to use buccal or cheek cells as a surrogate tissue from which to isolate sufficient nanogram amounts of mRNA that can be measured in proprietary custom designed microarray chips produced by Thermo Fisher Scientific for Ludwig. Buccal cells are ideal surrogate tissues for studying levels of mRNA.
Epigenetic regulation through mRNA is an important mode of cellular control in the development of cancer. Cancer development is a complex phenomenon that involves growth factors, cytokines and extracellular enzymes that shape the environment in the tissue as well as around the cancer. It is important to define the elements of mRNA transcripts that shape and sculpt the epigenome within each cell type during each cellular reprogramming event as well as how the changing epigenomes within the tumor and stroma can act in synergy during tumor progression.
Epigenetics is the study of how a person’s behaviors and environment can cause changes that affect the way your genes work. Unlike genetic changes, epigenetic changes are reversible and do not change your DNA sequence, but they can change how your body reads a DNA sequence.
Marvin S. Hausman MD, CEO, stated: “We may have discovered a potential holy grail in medicine that uses mRNA genetic information to allow early and more accurate prediction and diagnosis of disease and disease progression. Using this unique screening via mRNA biomarkers we have uncovered cancer genetic predisposition, and enable the establishment, on a personalized basis, treatment and response to therapy.”
$LUDG mRNA Bladder Cancer Study to be Launched
— Future Health Stocks (@FtrHealthStocks) January 31, 2024
The company announced it has received Continuing Review Approval on its planned clinical study from Advarra IRB, Columbia, MD.https://t.co/axJsVMe0ak
There was news out this month. Google LUDG. Should bring it up.Sure doesn't take much to take this one up
|
Followers
|
42
|
Posters
|
|
|
Posts (Today)
|
1
|
Posts (Total)
|
3149
|
|
Created
|
06/26/10
|
Type
|
Free
|
| Moderators GlitteringSeeker16 | |||
AI
